Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140


Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai.

Gu Y, Wang C, Zheng Y, Hou X, Mo Y, Yu W, Zhang L, Hu C, Nan H, Chen L, Li J, Liu Y, Huang Z, Han M, Bao Y, Zhong W, Jia W.

PLoS One. 2013;8(1):e53411. doi: 10.1371/journal.pone.0053411. Epub 2013 Jan 7.


Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.

Colhoun HM; SDRN Epidemiology Group.

Diabetologia. 2009 Sep;52(9):1755-65. doi: 10.1007/s00125-009-1453-1. Epub 2009 Jul 15.


Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort.

Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT.

J Clin Oncol. 2012 Jan 1;30(1):53-9. doi: 10.1200/JCO.2011.38.0303. Epub 2011 Nov 28.


Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.

Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N.

Diabetologia. 2012 Mar;55(3):644-53. doi: 10.1007/s00125-011-2429-5. Epub 2012 Jan 6.


Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.


Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.

Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, Grassi G.

Diabetes Obes Metab. 2012 Jan;14(1):23-9. doi: 10.1111/j.1463-1326.2011.01480.x. Epub 2011 Nov 21.


Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Hemkens LG, Grouven U, Bender R, G√ľnster C, Gutschmidt S, Selke GW, Sawicki PT.

Diabetologia. 2009 Sep;52(9):1732-44. doi: 10.1007/s00125-009-1418-4. Epub 2009 Jun 30.


Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.

Bo S, Castiglione A, Ghigo E, Gentile L, Durazzo M, Cavallo-Perin P, Ciccone G.

Eur J Endocrinol. 2013 Jun 7;169(1):117-26. doi: 10.1530/EJE-13-0299. Print 2013 Jul.


Type II diabetes mellitus and the incidence of epithelial ovarian cancer in the cancer prevention study-II nutrition cohort.

Gapstur SM, Patel AV, Diver WR, Hildebrand JS, Gaudet MM, Jacobs EJ, Campbell PT.

Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2000-5. doi: 10.1158/1055-9965.EPI-12-0867. Epub 2012 Aug 31.


Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.

Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ.

Diabetes Obes Metab. 2015 Apr;17(4):350-62. doi: 10.1111/dom.12412. Epub 2014 Dec 10.


Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.

Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH.

Diabetologia. 2012 Jan;55(1):51-62. doi: 10.1007/s00125-011-2312-4. Epub 2011 Sep 29.


Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.

Brunekreef B, Beelen R, Hoek G, Schouten L, Bausch-Goldbohm S, Fischer P, Armstrong B, Hughes E, Jerrett M, van den Brandt P.

Res Rep Health Eff Inst. 2009 Mar;(139):5-71; discussion 73-89.


Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults.

Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW Jr.

Cancer Causes Control. 1998 Aug;9(4):403-10.


Cancer occurrence in Danish diabetic patients: duration and insulin effects.

Carstensen B, Witte DR, Friis S.

Diabetologia. 2012 Apr;55(4):948-58. doi: 10.1007/s00125-011-2381-4. Epub 2011 Nov 27. Erratum in: Diabetologia. 2012 Apr;55(4):1223.


Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study.

Kim YI, Kim SY, Cho SJ, Park JH, Choi IJ, Lee YJ, Lee EK, Kook MC, Kim CG, Ryu KW, Kim YW.

Aliment Pharmacol Ther. 2014 Apr;39(8):854-63. doi: 10.1111/apt.12660. Epub 2014 Feb 20.


Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.

Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN, Mantzoros CS.

Metabolism. 2011 Oct;60(10):1363-71. doi: 10.1016/j.metabol.2010.09.012. Epub 2010 Nov 16.


Insulin use is not significantly predictive for prostate cancer mortality in diabetic patients: a 12-year follow-up study.

Tseng CH.

BJU Int. 2012 Sep;110(5):668-73. doi: 10.1111/j.1464-410X.2011.10924.x. Epub 2012 Feb 2.


Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study.

Monami M, Lamanna C, Pala L, Bardini G, Cresci B, Francesconi P, Balzi D, Marchionni N, Rotella CM, Mannucci E.

Exp Clin Endocrinol Diabetes. 2008 Mar;116(3):184-9. doi: 10.1055/s-2007-992157. Epub 2008 Feb 14.


Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.

van Staa TP, Patel D, Gallagher AM, de Bruin ML.

Diabetologia. 2012 Mar;55(3):654-65. doi: 10.1007/s00125-011-2390-3. Epub 2011 Nov 30.


Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.

Horsdal HT, Mehnert F, Rungby J, Johnsen SP.

J Stroke Cerebrovasc Dis. 2012 Nov;21(8):717-25. doi: 10.1016/j.jstrokecerebrovasdis.2011.03.007. Epub 2011 May 4.

Items per page

Supplemental Content

Write to the Help Desk